Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

Bio-IT World Conference 2020 presentation: A Network Polypharmacology Approach to Diffuse Intrinsic Pontine Glioma

Posted on March 5th, 2020 in Pharma R&D

The Bio-IT World Conference & Expo, taking place in Boston from April 21-23, is an annual event that brings together thousands of great minds to highlight technologies and analytic approaches to solving problems, accelerating science and driving the future of precision medicine.

(more…)

3 issues global pharmas should consider as the coronavirus outbreak continues

Posted on February 26th, 2020 in COVID-19

It has been more than four weeks since the Wuhan lockdown on January 23. As the crisis unfolded, spring festival national holidays were extended (and extended again), and finally people are now gradually going back to work—though some cities, towns and villages are still taking strict measures to prevent the virus spreading further.

(more…)

Life science community shares research to combat coronavirus

Posted on February 13th, 2020 in COVID-19

After weeks of rising concern about the rapid spread of the coronavirus in China’s Wuhan province, on January 31 the World Health Organization (WHO) declared it a global health emergency. But the story of the coronavirus outbreak is about more than a health scare – it is a terribly sad human tragedy. Already (as of this writing) over 40,000 people have been infected and over 1,000 have died since the outbreak began in December, and it is children and the elderly who have suffered most.

(more…)

FDA report shows 2019 was a strong year for innovation

Posted on February 10th, 2020 in Pharma R&D

Source: FDA.gov

On January 2, 2020, the FDA released the CDER annual report, stating that 2019 was “another strong year for innovation and advances.” The FDA cleared 48 new drugs for market, making it the second most productive year in the last decade (2018 approved 59 drugs). But given the fact that the total number of submissions have gone down, and that the American government was shut down for a lengthy period at the beginning of the year, the FDA delivered an impressive result in 2019.

(more…)

  1. 1
  2. 2
  3. 3
  4. 6